Canadian drug plans brace for 65% semaglutide price cut when third generic arrives

Canadian benefits analysts are warning plan sponsors that semaglutide list prices will drop to 35% of the brand price — a 65% cut — as soon as a third generic version reaches the Canadian market. Sandoz is now targeting the third quarter of 2026, and Aspen Pharmacare is pursuing a Canada-first launch ^[1].

The 65% figure comes from Canada's Pan-Canadian Pharmaceutical Alliance (pCPA) tiered pricing rules for generic semaglutide. Under those tiers, the first generic entrant is priced at 75% to 85% of the brand price, and the price falls to 35% of brand once three or more generics are on the market ^[1]. The trigger for the large cut is the third generic reaching the market, not the first approval. Health Canada has approved three of nine generic semaglutide products, according to a running approval tally ^[1].

Dr. Reddy's received its authorization on April 28, 2026, and Apotex is also approved ^[1]. Aspen's product, Aspen-Semaglutide, and a second product, Sevmia, appear in Health Canada's Drug Product Database listed as Approved but had no market date as of July 28, 2026, meaning neither could be bought yet ^[1]. The number of additional semaglutide files still under review has been reported at seven in early August 2026 and eight in September 2026, as the queue changes ^[1].

The opening for generics traces back to a patent decision. Novo Nordisk stopped paying a C$250 annual patent maintenance fee in 2018, a step that ultimately let generic semaglutide reach Canadian pharmacies in 2026 ^[1]. Patent expert Tahir Amin of the group I-MAK told the BBC that Novo Nordisk could have extended its Canadian Ozempic patent until 2028 but did not renew it ^[1]. Novo Nordisk has since launched a savings card that aligns Ozempic pricing with generics for uninsured Canadians, excluding Quebec, filled through Rexall pharmacies, and the company has guided to a 5% to 13% revenue decline for 2026 ^[1].

Why it matters for patients

The 65% cut applies to list prices, the published benchmark that plans and pharmacies negotiate from. Reports describe the size of the list-price change but do not spell out what an individual Canadian patient will pay at the counter under a given plan, and no per-patient cost figures have been disclosed ^[1].

Generic competition so far covers semaglutide only — the molecule in Ozempic, Wegovy and Rybelsus. Tirzepatide, sold as Mounjaro and Zepbound, is a different molecule, and no generic version has been reported as available in Canada. Sandoz has estimated its proposed generic tirzepatide at $200 to $400 per month and has filed US applications, while Eli Lilly raised Mounjaro KwikPen prices in Canada ^[1].

For US readers, the tiered trigger described in the Canadian coverage ^[1] has no reported US counterpart, and no US timeline for a similar automatic step-down has been reported. The price mechanics differ: Canadian list prices fall by rule once generic counts hit set thresholds, while US pricing runs through plan-by-plan negotiation.

Health Canada has also warned about counterfeit and unauthorized GLP-1 products. Advisory RA-81518 flags such products sold by retailers and online and urges purchases only from licensed pharmacies ^[1].

What happens next

• Sandoz is targeting the third quarter of 2026 for a third generic semaglutide entrant, the event that would flip pricing to the 35%-of-brand tier ^[1].
• Aspen's semaglutide is approved but had no market date as of July 28, 2026; the company has taken a Canada-first approach ^[1].
• Additional generic semaglutide files remain under review at Health Canada. The Canadian Generic Pharmaceutical Association says more than 500 generic submissions sit with the regulator, with 100 or more backlogged ^[1].
• Separately, Novo Nordisk won US approval for an oral Wegovy pill in December 2025, setting up 2026 competition with Eli Lilly's orforglipron ^[1].

What the 65% tier will mean for Canadian patients' actual out-of-pocket costs, and when a third generic will actually ship, has not been disclosed ^[1].